Evaluation of efficacy, safety and tolerability...

In the News

IHI at the first Malaria World Congress in Melbourne

(Melbourne) Ifakara Health Institute (IHI) was represented by three scientists to the inaugural Malaria World Congress in Melbourne, Australia. Research scientists, Dr. Gerry Killeen and Nancy Matowo took to the …

IHI researcher Nancy on Australian radio SBS

(Melbourne) Ifakara Health Institute (IHI) Research Scientist Nancy Matowo recently was invited to a 26-minute radio interview with the SBS, a Swahili Australian radio, to share her research work and …

Recent Projects

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

A Phase 3 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA‐824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug‐Sensitive Smear‐Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi‐Drug Resistant, Smear‐Positive Pulmonary Tuberculosis (STAND Trial).

The STAND trial, sponsored by the Global Alliance for TB Drug Development (TB Alliance) is a multi-center and multi-country study with over 50 study sites across Africa, Asia, Eastern Europe and Latin America. The trial is on the new three-drug regimen PaMZ for both TB and MDR-TB patients. In Tanzania the study is done in four sites: IHI (PI, Dr. Francis Mhimbira), Mbeya Medical Research Center-NIMR (PI, Dr. Issa Sabi), Kilimanjaro Clinical Research Institute (KCRI)-Moshi (Prof. Blandina Mmbaga) and NIMR-Mwanza (PI, Dr. George Praygod). The STAND trial is expected to run for 4 years. It is a Phase 3 Open‐Label Partially Randomized Trial.

Lead Scientists:

Francis Mhimbira

Frederick Haraka

Partners

National Institute of Medical Research
Kilimanjaro Clinical Research Institute
TB Alliance

Funders

No items found

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016